methylphenidate vs tranylcypromine
Side-by-side comparison of methylphenidate and tranylcypromine. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
Examples selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Antihypertensive Drugs Clinical Impact Methylphenidate hydrochloride extended-release capsules may decrease the effectiveness of drugs used to treat hypertension [see Warnings and Precautions ( 5.3 )] .
Recommendation: Your doctor may need to monitor your blood pressure and adjust your medication dosages.
Ritalin, Concerta
Parnate
Methylphenidate extended-release capsules are a stimulant medicine. They are used to treat Attention Deficit Hyperactivity Disorder (ADHD) in children ages 6 to 12.
Tranylcypromine (Parnate) is a medicine used to treat major depression in adults. It is used when other antidepressants have not worked well enough.
This medicine treats Attention Deficit Hyperactivity Disorder (ADHD) in children. ADHD can make it hard to focus, pay attention, and control impulsive behavior. This medicine can help improve focus and reduce hyperactivity.
Tranylcypromine is used to treat major depressive disorder (MDD) in adults. You should only use it if other antidepressants haven't helped. It is not for the first treatment of depression because it can cause serious side effects and has many drug and food interactions.
Methylphenidate is a central nervous system (CNS) stimulant. It works by affecting chemicals in the brain that contribute to hyperactivity and impulsivity. The extended-release capsules release the medicine in two stages, providing both an immediate and a delayed effect.
Tranylcypromine belongs to a class of drugs called MAO inhibitors. It works by increasing the levels of certain chemicals in your brain. These chemicals can help improve your mood.
- • Headache
- • Trouble sleeping (insomnia)
- • Upper abdominal pain
- • Decreased appetite
- • Loss of appetite (anorexia)
- • Dry mouth
- • Dizziness
- • Trouble sleeping
- • Feeling sleepy
- • Headache
- Problem with the quality of the medicine 5,241
- Mistake in giving the medicine 1,901
- Incorrect way of using the medicine 1,772
- Redness where the medicine was applied 1,684
- Skipping a dose of the medicine 1,478
- Interaction between medicines 68
- Feeling sad or hopeless 36
- Too much serotonin in the body 27
- Head pain 24
- High blood pressure 24
This medicine has a high potential for abuse and dependence. Your doctor will assess your risk before prescribing it and monitor you during treatment. Misuse of this medicine may cause sudden death or serious heart problems.
Tranylcypromine can increase the risk of suicidal thoughts and behaviors in young adults. It can also cause a dangerous increase in blood pressure if you eat foods high in tyramine or take certain medicines. Make sure to follow all food and drug restrictions.
Tell your doctor if you are pregnant or plan to become pregnant. It is not known if this medicine will harm your unborn baby. There is a pregnancy registry for women who take ADHD medicines during pregnancy.
There is limited information about the safety of tranylcypromine during pregnancy. Talk to your doctor if you are pregnant or plan to become pregnant. It is not recommended to breastfeed while taking this medicine because it can harm the baby.
Also Compare, Nearby Drugs
Compare methylphenidate with
Compare tranylcypromine with
How to Read This methylphenidate vs tranylcypromine Comparison
methylphenidate is classified in the CNS Stimulant drug class, while tranylcypromine sits within the Monoamine Oxidase Inhibitor (MAOI) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, methylphenidate has 12,076 submissions while tranylcypromine has 179. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to methylphenidate can raise blood pressure, which makes drugs used to lower blood pressure work less effectively.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between methylphenidate and tranylcypromine - always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.